Arete Therapeutics Reports Positive Phase I Data For AR9281

Arete Therapeutics Inc. announced positive top line Phase I results for AR9281, an orally-administered soluble epoxide hydrolase (s-EH) inhibitor for the treatment of metabolic syndrome. The results of the multi-dose study demonstrate that AR9281 was safe and well tolerated in healthy volunteers.

More: continued here

Filed under: Endocrinology on January 4th, 2009